Trial Profile
Phase II Randomized, Double-blind, Placebo-controlled Study of LEE011(Ribociclib) or Placebo in Combination With Endocrine Therapy for the Treatment of Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer, Including a Subset With Pharmacokinetic Analysis
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs Anastrozole (Primary) ; Letrozole (Primary) ; Ribociclib (Primary) ; Goserelin
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 02 May 2022 Planned End Date changed from 13 Dec 2023 to 11 Dec 2024.
- 07 Mar 2022 Planned primary completion date changed from 28 Feb 2022 to 25 Apr 2022.
- 16 Jul 2021 Planned primary completion date changed from 30 Jun 2021 to 28 Feb 2022.